Adam Kovalčík, a 19-year-old from Slovakia, won the world’s top award with a new molecule designed by computer simulation! These molecules are expected to effectively prevent viral replication like the broad-spectrum antiviral drug Galidesivir. He paid special attention to one of the molecules called ADK-98, thinking that the effect may be better. More groundbreaking is that the new method proposed by Adam will reduce the overall production cost of each gram of drug by 625%. This new synthesis method is expected to bring substantial breakthroughs to the global fight against RNA viruses. With this discovery, he won the first prize of the 2025 Regeneron ISEF International Science and Engineering Fair (Regeneron ISEF) and the $100,000 George D. Yancopoulos Innovation Award

Adam Kovalčík’s Breakthrough in Antiviral Drug Synthesis

Adam Kovalčík, a 19-year-old from Dulovce, Slovakia, won the top honor at the 2025 Regeneron International Science and Engineering Fair (ISEF), securing the $100,000 George D. Yancopoulos Innovator Award for his pioneering work in antiviral drug synthesis.

Key Achievements

– Cheaper, Faster Synthesis of Galidesivir
  – Kovalčík developed a novel, more efficient method to synthesize *galidesivir*, an experimental broad-spectrum antiviral drug targeting RNA viruses such as COVID-19, Ebola, and Zika.
  – His process uses *furfuryl alcohol* derived from corn husk waste as a starting material, reducing the number of synthetic steps from 15 to 10 and the production time from 9 days to 5.
  – This innovation slashed the production cost from approximately $75 per gram to about $12.50 per gram—an 83% reduction, making the drug much more accessible and affordable.

– Creation of a New Antiviral Molecule
  – By leveraging computer simulations, Kovalčík designed new molecules expected to inhibit viral replication more effectively than galidesivir.
  – One standout candidate, *ADK-98*, showed in early computer modeling to potentially be up to five times more effective against COVID-19, due to stronger binding to viral enzymes critical for replication.
  – The approach not only streamlines galidesivir production but also enables the synthesis of novel antiviral compounds, broadening the arsenal against RNA viruses.

– Innovative Synthesis Methodology
  – The process is *stereoselective*, favoring the production of the more potent *cis*-OH galidesivir, which is about 20 times more effective than its *trans* isomer.
  – Kovalčík’s method minimizes the need for costly separation steps, further reducing manufacturing complexity and waste.

Scientific and Social Impact

– Global Health Implications
  – If Kovalčík’s synthesis method is adopted at scale, it could dramatically improve the availability and affordability of antiviral drugs, especially in resource-limited settings.
  – The new molecule, ADK-98, holds promise for future drug development, potentially offering a more effective treatment option for a range of RNA viral infections.

– Recognition and Future Plans
  – Kovalčík’s work was praised for its thoroughness and innovation by the ISEF judging panel, and he has filed a preliminary patent for his synthesis process.
  – He plans to collaborate further with research teams at the Slovak University of Technology and aims to expand his work into other drug synthesis processes and even eco-friendly perfume production using corn byproducts.

Conclusion

Adam Kovalčík’s innovation represents a major advance in antiviral drug manufacturing. By dramatically reducing costs, simplifying production, and enabling the creation of new, potentially more effective antiviral molecules, his work could have a lasting impact on the fight against RNA viruses worldwide.